Newspaper Publication of Financial Results for the quarter and nine months ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Limited has published its unaudited standalone financial results for the quarter and nine months ended December 31, 2025 in Business Standard and Andhra Prabha newspapers, as required under SEBI listing rules. For Q3 FY26, total income from operations stood at Rs. 2,220.06 lakhs, down from Rs. 2,964.97 lakhs in Q3 FY25, while net profit after tax was Rs. 75.76 lakhs versus Rs. 76.74 lakhs in the year-ago quarter, with EPS of Rs. 1.01. For the nine months ended December 2025, total income was Rs. 7,330.89 lakhs (vs Rs. 8,871.96 lakhs in 9M FY25) and net profit after tax was Rs. 279.84 lakhs (vs Rs. 348.69 lakhs), translating to an EPS of Rs. 3.72 versus Rs. 4.63. Results were approved by the board on February 11, 2026.
Year-on-year revenue and profit are lower across both the quarter and nine-month period, signalling some top-line pressure, though the sequential quarter shows the company remains profitable. Shareholders may view this as a modest slowdown, but the company continues to post positive earnings with stable margins.